Celularity Closes $10M Initial Financing in Up to $28M Recapitalization
CELU has more than doubled off its 52-week low of $0.56.
Summary
Celularity closed an initial $10 million tranche of a recapitalization that could reach $28 million, combining up to $25 million in new capital with restructuring of $3 million in existing debt. The financing includes senior secured convertible notes and warrants, with conversion and exercise prices set at $1.50 per share. Philip A. Barach, a major shareholder who previously provided a bridge loan, joins the board. Management expects positive monthly operating cash flow by the end of Q1 2027, supported by reduced cash burn and an estimated $40 million in potential sales from existing cenplacel-L inventory. This follows a period of Nasdaq compliance issues and leadership changes, making the capital infusion a critical step toward stability. The deal is highly dilutive at current prices but signals insider confidence and provides runway for commercial execution.
Updates
· SEC 8-K — The initial closing was $11.01 million, not $10 million, with notes convertible at $1.50 into about 7.34 million shares and warrants for 4.037 million shares. Celularity also settled with Helena, issuing 2.7 million shares and converting $1.197 million of debt.
At the time of this announcement, CELU was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.56 to $2.55. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.